Basilea awarded CARB-X grant of up to USD 2.7 million to develop novel-class antibiotic May 19, 2021 01:15AM
Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics Apr 24, 2019 12:29PM
Pfizer Enters into Agreement to Develop and Commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific Region Dec 1, 2017 01:22AM
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel Jul 20, 2017 01:16AM
Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel Jun 14, 2017 01:16PM


May 4, 2015 01:53PM Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor
Apr 1, 2015 01:17AM Basilea in-licenses targeted cancer therapy